Innate Immunotherapeutics, whose largest shareholder is Buffalo-area Rep. Chris Collins, received FDA approval to begin U.S. trials of its drug for treating advanced multiple sclerosis.
Tom Price defends proposed spending reductions in Medicaid and other HHS programs while demurring on questions about cost-sharing subsidies for the 2018 Obamacare marketplace.
In the early stages of the Senate’s attempts to write a health care bill, a Republican and a Democrat each solicit constituents’ Obamacare experiences from opposite ends of the spectrum.
The two Republican lawmakers sent a letter to HHS Secretary Tom Price warning him that whistleblowers in HHS could be intimidated into silence by a department memo instructing employees to get clearance before talking with members of Congress and their staffs.
The advocacy group behind an expensive media blitz opposing Canadian drug imports has deep ties to the drug industry’s largest trade group.
Democratic senators want the Justice Department to reveal what it knows about ProPublica’s recent report that HHS Secretary Tom Price’s stock trades were under investigation by former U.S. Attorney Preet Bharara before the Trump administration fired him.
Sen. Bernie Sanders’ bill to allow Americans to buy cheaper medicines from Canada would bypass a requirement that blocked past legislative efforts over two decades.
The HHS Secretary bought stock in companies that stood to benefit from legislation he voted for and sponsored as a Georgia congressman.
Acting administrator Andy Slavitt is taking to social media to defend the Affordable Care Act from GOP dismantling.
Price and another influential GOP congressman got a discounted deal as an Australian firm seeking federal approval sought “sophisticated U.S. investors.”